

Pulse Dose Methylprednisolone Therapy in a Cohort of very Severe COVID-19 Patients in a Resource-limited setting in Myanmar: A Case Series of 13 patients

ABSTRACT

Aims: Coronavirus disease 2019 (COVID-19) has very high mortality in severe forms of disease, where immunopathology plays an important role. Use of immunomodulating therapies including 6 to 12 mg of dexamethasone is well established. Higher doses of corticosteroids were used with reported success in some settings. This study aims to explore the role of pulse dose methylprednisolone therapy in very severe COVID-19 patients in preventing the need for ICU care and death in resource-limited setting.

Study design: Retrospective case series study

Place and Duration of Study: Oak-ta-chat-thal-ta-pwint COVID-19 treatment center in Yangon, Myanmar between September 2021 to December 2021.

Methodology: This study included 13 confirmed COVID-19 patients with severe to critical illness, who were treated with pulse dose methylprednisolone therapy. We reviewed the patients' demographics, comorbidities, and disease severity before starting pulse dose methylprednisolone therapy and changes in oxygen requirement, chest X-ray scores, inflammatory markers, development of significant clinical events, and 28 days mortality after therapy.

Results: Before pulse dose methylprednisolone therapy, all 13 patients had very severe disease (mean $\text{SPO}_2/\text{FiO}_2 = 173$ mmHg, mean $\text{SPO}_2 = 88.54\%$, mean CRP = 115 mg/L, mean ferritin = 1,295.5 ng/mL and mean Brixia Score = 6.54). They received 3-7 days (mean = 5.5 days) of pulse dose methylprednisolone. Ten patients (76%) survived in a setting with limited ICU care. High ferritin was a significant predictor of mortality. Improvement in oxygen requirement was noticeable after 1-11 days (mean = 5.6 days). Hyperglycemia was common and confirmed bacterial infection was found in 3 patients, but all patients received empirical antibiotics therapy.

Conclusion: Pulse-dose methylprednisolone therapy may be an effective salvage therapy in a carefully selected subset of very severe COVID-19 patients. It might be a feasible alternative to other more expensive immunomodulating agents and organ support treatments in a resource-limited setting.

Keywords: COVID-19, Pulse dose corticosteroid, methylprednisolone, resource-limited settings

1. INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a pandemic disease caused by a novel corona virus SARS-Cov-2. Recently, the world health organization declared an end to COVID-19 as a disease of a public health emergency. Yet, many mysteries remain about the

disease. Since its emergence in 2019, more than six million lives have been lost to this disease [1]. Hypoxic respiratory failure due to **Adult Respiratory Distress Syndrome (ARDS)** and multisystem failure due to cytokine release syndromes are significant events in critical cases of COVID-19. Immunopathology plays a major role in these critical stages of COVID-19 [2].

The use of low to **moderate-dose** dexamethasone therapy in severe COVID-19 has been well accepted [3]. In very severe cases, thrombo-inflammation in the lungs and alveolar damage progress despite low-dose dexamethasone and antiviral agents, requiring ventilatory support and advanced ICU care. The prognoses in these patients are very poor despite every effort with the use of advanced ICU supports [4,5]. In a resource-limited setting, advanced life supports are practically almost unavailable during a pandemic crisis and entering a critical stage in COVID-19 is usually a one-way downward spiral to death. The pathogenesis in these later stages of disease is mainly due to aberrant and dysfunctional inflammatory response and suppressing the inflammatory response theoretically might benefit.

Corticosteroids are potent non-specific immunosuppressive and anti-inflammatory agents [6]. They are also widely available in every setting and their use has been familiar to most clinicians for their historical use in severe autoimmune conditions. Various doses of corticosteroids were reportedly used in severe COVID-19 and the role of high-dose corticosteroids is still uncertain. The studies on **high-dose** corticosteroids in severe COVID-19 were mainly retrospective observational studies and the success rate has been varied due to the use of various doses of drug and choice of patients [7–19]. There are also concerns for potential harms like **delayed** viral clearance and superimposed infections. **Short-term** use of supra-physiological doses of corticosteroids is believed to act through a nongenomic pathway to downregulate immune cell activation and proinflammatory cytokine production [20]. We hypothesized that the high-dose corticosteroid would be beneficial if it is given in a critical time window at the start of severe unchecked inflammation.

This study aimed to explore the role of pulse dose methylprednisolone therapy in very severe COVID-19 patients in preventing the need for ICU care and death. The specific objectives were to describe the characteristics of patients treated with high-dose methylprednisolone therapy, ascertain the timing from disease onset and severity status at the initiation of pulse dose therapy, and describe the outcomes and complications of these patients.

2. METHODOLOGY

This study reports a case series of 13 patients who were treated with pulse dose methylprednisolone therapy. The study was done in a temporary COVID-19 treatment facility in Yangon, Myanmar. The study was conducted from September to December 2021, when the delta B.1.617.2 strain of SARS-Cov2 was actively transmitting in the country, coinciding with the later part of the catastrophic "third wave". All patients admitted to the facility during the study period were reviewed for eligibility. There was no sample size calculation and all patients who received the therapy of interest during the study period were included. All adult patients more than 18 years of age with confirmed COVID-19 disease and who received pulse dose methylprednisolone therapy (defined as methylprednisolone ≥ 250 mg or equivalent for at least 3 consecutive days by clinician discretion) were included in the review. The variables of interest were extracted from the inpatient medical records of the electronic medical record systems. Outcomes data were extracted from the routine telephone follow-up record of the treatment facility until 28 days from the date of admission. Mortality status (death or survival) was the main outcome and receiving Pulse-Dose Methylprednisolone Therapy (PDMPT) was related to changes in SPO_2/FiO_2 status, Brixia Score before and after PDMPT, and biochemical markers (CRP, ferritin, and lymphocytes) were predictors; age and

gender are potential confounders and days of COVID 19 and underlying co-morbidity and use of other immunomodulators were effect modifier. The age, sex, and underlying comorbid conditions were extracted from the initial clinical assessment record by the admitting medical officer. The dose and total duration of high-dose corticosteroid therapy was taken from the highest dose of corticosteroid which the patient received during admission and the duration of that dose, irrespective of the tapering doses or if-any previous smaller doses. The timing of therapy initiation was measured by days from the onset of symptoms and the severity of disease at the initiation was measured by oxygen requirement ($\text{SaO}_2/\text{FiO}_2$ ratio estimated from the dose of oxygen and pulse oximetry measurement), chest X-ray scores (Brixia score by Borghesi and Maroldi, 2020 [21]) and biochemical markers of inflammation. Any other treatments received were also recorded and they were grouped into antiviral agents, anti-thrombotic, other immunomodulators, and antibiotics.

Any event after initiation of therapy until discharge was analyzed as potential complications of therapy. Infection was defined as any event of culture-confirmed or clinically suspected infection, requiring antibiotics therapy. Hyperglycemia was new onset or worsening hyperglycemia requiring any treatment or diet modifications. The clinical severity of the disease was classified as asymptomatic, mild, moderate, and severe, or critical as defined by the COVID-19 treatment guideline by the National Institute of Health [22]. Data were extracted and synthesized in excel spreadsheet. Statistical analysis was done with SPSS version 20. Regarding descriptive statistics, categorical data were analyzed using frequency table and continuous data were analyzed using mean (SD), median (IQR) and 95%CI in accordance with their distribution. Chi square test was used for inferential statistics and statistical significance was set at alpha value of 0.05.

3. RESULTS

A total of 13 patients received 3-7 days course of IV methylprednisolone therapy. Twelve patients received 1 G of methylprednisolone each day while only 1 patient was given 250mg of methylprednisolone therapy. Most of them (n=11) were also given oral Baricitinib and 9 patients also received two doses of tocilizumab (according to availability). CRP level was the earliest to fall after high-dose steroid therapy and improvement in hypoxia was noticeable only after 1-11 days with a mean duration of 5.6 days.

Table 1: Description of 13 COVID-19 cases under the study following their outcomes.

Variables	Outcomes		Total	Significant Test p-value "p"	Remark
	Alive n (%)	Death n (%)			
Age Group					
≤ 40 years				Fisher Exact Test $\chi^2 =$	
≥ 41-60 years	1 (100)	0 (0)	1 (7.7)	0.795	
> 61 years	5 (71.4)	2 (28.6)	7 (53.8)	"p" = 1.00	

Minimum age: 27 years Maximum age: 85 years Mean (\pm SD): 56.63 \pm 14.86 years	4 (80)	1(20)	5 (38.5)		
Gender Male Female	4 (57.1) 6 (100)	3 (42.9) 0 (0)	7 (53.8) 6 (46.2)	Fisher exact $X^2 = 5.424$ "p" = 0.192	
Comorbidity * Yes No *Diabetes, Hypertension, Ischemic Heart Disease, Obesity, Peripheral Vasculopathy	8 (80) 2 (66.7)	2 (20) 1 (33.3)	10 (79.9*) 3 (23.1*)	$X^2 = 0.231$ "p" = 1.00	
Risk for Severe COVID Yes (\geq 61 years \pm underlying d/s) No (\leq 60 without underlying d/s)	8 (80) 2(66.6)	2 (20) 1 (33.3)	10 (76.9*) 3 (23.1*)	$X^2 = 0.231$ "p" = 1.00	
Steroid duration (days) Minimum days Maximum days Mean \pm SD	3 7 5.5 (\pm 1.84)	5 5 5 (\pm 0.0)		95% CI of the difference lower (-1.19) upper(2.93)	
Days from the start of steroid to improve in hypoxia Minimum days Maximum days Mean \pm SD	1 10 5.4 (\pm 3.41)	4 11 6.33 (\pm 4.04)		95% CI of the difference lower (-6.09) upper(4.22)	
Additional immunosuppressive Baricitinib Nil Tocilizumab, Baricitinib	 3 (100) 1 (100) 6 (66.6)	 0 (0) 0 (0) 3 (33.4)	 3 (23.1) 1 (7.7) 9 (69.2)	$X^2 = 1.501$ "p" = 0.27	

Symptoms days before admission				$\chi^2 = 0.258$ "p" = 1.000	
<7 days	5 (83.3)	1 (16.7)	6 (46.2)		
≥7 days	5 (71.4)	2 (28.6)	7 (53.8)		

Table 2. Comparison of disease severity status before PDMP therapy of 13 COVID-19 cases under study following outcomes

Disease severity parameters	Outcomes		Total	Significant Test p-value ("p")	Remark
	Alive	Death			
SPO₂/FiO₂ Before Steroid Therapy				95% CI of the difference lower (-130.06) upper (79.59) "p"= 0.61	
Minimum	96	100	96		
Maximum	303	240	303		
Mean (± SD)	168 (± 22.2)	193 (± 46.67)	173 (± 19.46)		
CRP Before Steroid Therapy				95% CI of the difference lower (-96.74) upper (112.13) "p"= 0.87	
Minimum	44.3	68.1	44.3		
Maximum	264.8	151.5	264.8		
Mean (± SD)	117(±2 4.4)	109.9 (± 46.67)	115 (± 10.16)		
Lymphocytes Before Steroid Therapy				95% CI of the difference lower (-0.76) upper (0.97)	
Minimum	0.37	0.63	0.37		
Maximum	2.47	1.05	2.47		
Mean (± SD)	0.96 (± 0.21)	0.86 (± 0.12)	0.93 (± 0.57)		
Ferritin Before Steroid Therapy				95% CI of the difference lower (-2,854.74) Upper (455.07)	
Minimum	204	1392	204		
Maximum	1902	3001	3001		
Mean (± SD)	944.76 (± 216.42)	2464.67 (± 536.3)	1295.5 (± 268.8)		

Lowest SPO2 at Home					
Minimum days	75	88	75	95% CI of the difference	
Maximum days	93	92	93	lower (-8.7)	
Mean \pm SD	88.2(\pm 1.718)	89.67 (\pm 1.2)	88.54(\pm 1.33)	upper (5.77)	



UNDER PEER REVIEW

Table 3. Case Summary of 13 severe COVID-19 patients treated with pulse dose methylprednisolone therapy.

Cas e No	A g e	Sex	Comorbid ities	SP O 2/ Fi O 2	CRP	Lymp hocyt e	Ferr itin	Bri xia sc or e	Ster oid dose	Ster oid dura tion	Additional immunos uppressiv es	Events after treatment	Final Outco me
1	60	F	Peripheral vascular disease	95.83	59.86	0.41	3267	7	1G	7	tocilizumab, baricitinib	Hyperglycemia	survive
2	43	F	Nil	101.04	73.23	1.01	20410	10	1G	7	tocilizumab, baricitinib	Hyperglycemia, Bacterial pneumonia	survive
3	72	F	Hypertension, cardiovascular disease	194.00	264.76	1.09	411.3	2	250mg	5	tocilizumab, baricitinib	Hyperglycemia, GI bleeding	survive
4	42	M	obesity, hypertension	98.96	108.9	0.37	1621	10	1G	6	tocilizumab, baricitinib	Hyperglycemia, Staphylococcus bacteremia,	survive

												Fungal infection	
5	55	M	obesity	98.96	75.35	2.47	1902	10	1G	7	tocilizumab, baricitinib	Hyperglycemia, Septicemia	survive
6	61	M	Hypertension, coronary artery disease, obesity	100.00	151.46	0.63	1392	10	1G	5	tocilizumab, baricitinib	GI bleeding, hyperglycemia, Pulmonary edema	die
7	55	M	hypertension	240.00	110.41	0.9	>3000	8	1G	5	tocilizumab, baricitinib	Hyperglycemia, GI bleeding, CNS thrombosis	die
8	59	M	Nil	240.00	68.1	1.05	>3000	4	1G	5	tocilizumab, baricitinib	Hyperglycemia	die
9	85	M	Hypertension, coronary artery disease	240.00	99.15	0.43	1539.3	6	1G	7	tocilizumab, baricitinib	Hyperglycemia	survive

10	27	F	Nil	194.00	79.07	1.33	170.7	6	1G	7	baricitinib	Hyperglycemia, GI bleeding	survive
11	65	F	diabetes	165.00	250.43	0.45	885.9	2	1G	3	nil	Hyperglycemia, Septic shock	survive
12	46	F	hypertension	303.13	44.3	1.36	253.7	7	1G	3	baricitinib	Hyperglycemia	survive
13	67	M	Coronary artery disease, benign prostate hypertrophy, renal stones disease	190.00	121.87	0.71	487.4	3	1G	3	baricitinib	Hyperglycemia, shock	survive






Figure 1. Box plots showing serial changes in disease severity parameters after PDMPT. Day 1 represents the first day of PDMPT. The horizontal line within each box represents the median and the cross represents the mean, the lower and upper border of each box represent the lower and upper quartiles and the T bar represents 1.5 x IQR and the dots are outliers. For measurement of hypoxia, SpO_2/FiO_2 was used as an estimate of PaO_2/FiO_2 , with the value of 200-300 representing mild degree, 100-200 representing moderate degree, and <100 representing severe degree of ARDS.

4. DISCUSSION

In this study, we reported the outcome of 13 very severe COVID-19 cases, treated with pulse dose methylprednisolone therapy. These patients were treated in a time of pandemic crisis in a very resource-limited setting where advanced ICU care was practically unavailable. Pulse dose methylprednisolone therapy was used as a last resort salvage therapy and we could save 76% of them.

Current treatment guidelines for COVID-19 recommend 6-12 mg of dexamethasone in severe cases requiring oxygen therapy [3]. This recommendation was based on the results of clinical trials randomizing all severe patients and the lack of statistically significant results in comparison with a slightly larger dose of dexamethasone. However, we experienced certain subgroups of patients whose COVID-19-related alveolar damage and markers of inflammatory responses were not adequately controlled and who were at imminent risk of progressing into the critical stage. In those patients, we tried pulse dose methylprednisolone therapy with the hope that the dose-dependent non-specific immunosuppressive and anti-inflammatory effect of corticosteroids might rescue those hopeless patients. There were also reports of successful uses of similarly high doses of corticosteroids. These studies were small retrospective observational studies. There were also mixed results with different studies using different doses and different criteria for starting high-dose corticosteroids.

In those studies, the benefits of high-dose corticosteroids were seen in terms of mortality [7,13]), oxygen requirement [16], ICU admission [13], and inflammatory markers [17]. These benefits were found especially in age less than 70 years of age (7) and if given not too early or too late [16]. Tromp et al (2021) also reported that high-dose corticosteroid therapy with methylprednisolone 1000mg/day for 3 days did not increase viral replication [17]. However, a recent systematic review and meta-analysis of 12 studies involving 2759 patients reported that high-dose corticosteroid was not better than conventional dose corticosteroid [15]. The trials in this meta-analysis used various doses, duration, and regimens of high-dose corticosteroids, resulting in high heterogeneity. A retrospective cohort study by Yaqoob et al (2022) also found that pulse dose steroid (MP 1G/day) was not better

than the conventional dose, with a higher rate of acute kidney injury [18]. However, this study was done in patients admitted already to ICU, which is different from our patient population who are mostly inaccessible to ICU care. Another cohort study of 573 patients also reported higher mortality with corticosteroid doses higher than 250mg/day [12]. In this study, remdesivir use was one of the exclusion criteria and it may be one reason why more intensive immunosuppression resulted in higher mortality due to unchecked viral replication.

In our cohort of patients, we used higher doses of corticosteroids (1 gram of methylprednisolone for 3 to 7 days) and we started this regime as soon as the standard treatment was not working. The criteria for initiation were high oxygen requirement of more than 10 liter/minute, more than 50% of parenchymal involvement in chest X-rays, and high inflammatory markers in the absence of confirmed or suspected co-infection. Rapid progression of disease severity in terms of oxygen requirement and serial chest X-rays was also an important factor in considering the more aggressive treatment. All of our patients were also treated with intravenous remdesivir for 5 days. Intravenous tocilizumab was also given if the patient afforded the cost of the drug. However, this therapy was hard to start immediately since it was not readily available at the time. Nine out of 13 patients received tocilizumab therapy while the other 4 did not. The outcome was not significantly associated with the addition of additional immunomodulator therapy like tocilizumab. All 4 patients who could not afford this therapy survived but some treated with tocilizumab were lost.

After initiation of therapy, CRP levels invariably fall after a day or two but rise again in the 3rd week in some cases (Figure 1.). Superimposed infection was identified in some of those cases and successfully treated. However, improvement in oxygen level was noticeable only after a week. Ferritin level and Chest X-ray scores showed no noticeable changes after PDMPT until 3 weeks of follow-up. This can be explained by the fact that serum ferritin was not frequently measured in our cohorts and the follow-up period was short to detect the usually slow radiological improvements. In two cases of mortality, there was no improvement in hypoxia, and CRP level rise again after initial falling. This indicates that inflammatory response was not adequately controlled or smoldering co-infection might have been missed. These cases had very high ferritin and CRP before starting PDMPT. In the third case of mortality, oxygenation, and inflammatory markers improved but the patient was lost due to a CNS complication, a thrombotic event, or infection, which we could not confirm. High ferritin was only significantly associated with mortality in our cohort.

Generally, the cases we treated with PDMPT were very severe from the outset and failed to respond to standard treatments. Remdesivir and PDMPT (in combination with tocilizumab in some cases) successfully rescued most of them, even in a setting without advanced ICU care. Hyperglycemia was very common after PDMPT as expected and empirical antibiotics therapies were used in all cases, but the definitive infective infection was proved only in three cases.

We recommend further randomized controlled trials of pulse dose methylprednisolone therapy in very severe COVID-19 patients with high oxygen requirement, diffuse parenchymal involvement in chest X-rays or rapidly changing X-rays, and high markers of inflammation. Since contextual factors like the availability of high ends, and supportive care are varied in different healthcare settings, defining healthcare resources settings in future trials might be useful. We observed several limitations of this study. First, we reported the story of a small number of cases, and these cases were not randomly selected, limiting the generalizability of the study results. The cases were followed up for only 28 days and we did not study the long-term complications.

5. CONCLUSION

Intravenous Pulse dose of methylprednisolone 1 gram per day for 3 to 7 days might be an effective salvage therapy for very severe COVID-19 patients. This is especially

hopeful for patients in resource-limited settings. Future studies are warranted in carefully selected populations of very severe diseases.

CONSENT

Written informed consent was obtained from the patient or the next of kin for publication of this case series.

ETHICAL APPROVAL

All authors hereby declare that this study was approved by the local ethics committee and has therefore been performed following the ethical standards laid down in the 1964 Declaration of Helsinki.

REFERENCES

1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2023 May 25]. Available from: <https://covid19.who.int/>
2. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. *Nature Reviews Microbiology* 2022 20:5 [Internet]. 2022 Mar 30 [cited 2023 May 25];20(5):270–84. Available from: <https://www.nature.com/articles/s41579-022-00713-0>
3. Corticosteroids | COVID-19 Treatment Guidelines [Internet]. [cited 2023 May 28]. Available from: <https://www.COVID19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/>
4. Anesi GL, Jablonski J, Harhay MO, Atkins JH, Bajaj J, Baston C, et al. Characteristics, Outcomes, and Trends of Patients With COVID-19-Related Critical Illness at a Learning Health System in the United States. *Ann Intern Med* [Internet]. 2021 May 1 [cited 2023 May 28];174(5):613–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/33460330/>
5. Biccard BM, Gopalan PD, Miller M, Michell WL, Thomson D, Ademuyiwa A, et al. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. *Lancet* [Internet]. 2021 May 22 [cited 2023 May 28];397(10288):1885–94. Available from: <https://pubmed.ncbi.nlm.nih.gov/34022988/>
6. Suran K, Pushpa S. Pulse therapy – A newer approach. *Indian Journal of Multidisciplinary Dentistry*. 2017;7(1):41.
7. Climente-Martí M, Ruiz-Millo O, López-Cruz I, Atienza-García Á, Martínez-Moragón E, Garijo-Gómez E, et al. Impact of intermediate to high doses of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation. *Int J Clin Pract*. 2021 Sep 1;75(9).
8. Fan Q, Deng K, Huang H, He R, Deng X, Lan Y, et al. Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients. *Front Immunol*. 2022 Mar 8;13.
9. Go RC, Nyirenda T, Bojarian M, Hosseini DK, Kim K, Rahim M, et al. Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia. *BMC Infect Dis*. 2022 Dec 1;22(1).
10. Kumar V, Kashyap A, Kaur S, John M, Sibia R, Chopra V, et al. Comparison of Tocilizumab and High-dose Methylprednisolone Pulse on Outcomes in Severe Corona Virus Disease-2019: TAME-COVID, a Retrospective Multicentric Study. *Int J Appl Basic Med Res* [Internet]. 2021 [cited 2022 Mar 14];11(4):263. Available from: <https://pubmed.ncbi.nlm.nih.gov/34912692/>

11. Lim PC, Wong KL, Rajah R, Chong MF, Chow TS, Subramaniam S, et al. Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis. Vol. 30, DARU, Journal of Pharmaceutical Sciences. Springer Science and Business Media Deutschland GmbH; 2022. p. 211–28.
12. Monreal E, Sainz de la Maza S, Natera-Villalba E, Beltrán-Corbellini Á, Rodríguez-Jorge F, Fernández-Velasco JI, et al. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. *European Journal of Clinical Microbiology and Infectious Diseases*. 2021 Apr 1;40(4):761–9.
13. Pinzón MA, Ortiz S, Holguín H, Betancur JF, Arango DC, Laniado H, et al. Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia. *PLoS One* [Internet]. 2021 May 1 [cited 2022 Dec 27];16(5). Available from: <https://pubmed.ncbi.nlm.nih.gov/34033648/>
14. Ro S, Nishimura N, Imai R, Tomishima Y, So C, Murakami M, et al. Identification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy.
15. Tan RSJ, Ng KT, Xin CE, Atan R, Yunus NM, Hasan MS. High-Dose versus Low-Dose Corticosteroids in COVID-19 Patients: a Systematic Review and Meta-analysis. *J Cardiothorac Vasc Anesth*. 2022 Sep 1;36(9):3576–86.
16. Tokano M, Tarumoto N, Imai K, Sakai J, Ishibashi N, Yokota K, et al. Timing of Initiation of Methylprednisolone Pulse Therapy in Patients with COVID-19. *COVID*. 2022 Apr 21;2(5):532–9.
17. Tromp K, van der Zee P, Rokx C, van Kampen J, Gommers D, Endeman H. Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study. Vol. 16, *Biomarker Insights*. SAGE Publications Ltd; 2021.
18. Yaqoob H, Greenberg D, Hwang F, Lee C, Vernik D, Manglani R, et al. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit. *J Med Virol*. 2022 Jan 1;94(1):349–56.
19. Zúñiga MÁL, Moreno-Moral A, Ocaña-Granados A, Padilla-Moreno FA, Castillo-Fernández AM, Guillamón-Fernández D, et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. *PLoS One* [Internet]. 2021 Jan 1 [cited 2023 May 17];16(1):e0243964. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243964>
20. Kumar A, Singh S, Sherawat V. Pulse therapy – A newer approach. *Indian Journal of Multidisciplinary Dentistry*. 2017 Oct 26;8(11):1739.
21. Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. *Radiologia Medica* [Internet]. 2020 May 1 [cited 2023 May 17];125(5):509–13. Available from: <https://link.springer.com/article/10.1007/s11547-020-01200-3>
22. Clinical Spectrum | COVID-19 Treatment Guidelines [Internet]. [cited 2023 May 17]. Available from: <https://www.COVID19treatmentguidelines.nih.gov/overview/clinical-spectrum/>

DEFINITIONS, ACRONYMS, ABBREVIATIONS

ARDS: acute respiratory distress syndrome

COVID-19: Coronavirus disease 2019

CRP: C-reactive protein level in serum

ICU: intensive care unit

PDMP: pulse dose methylprednisolone therapy

SPO₂: peripheral capillary oxygen saturation

SPO₂/FIO₂: ratio of peripheral capillary oxygen saturation to the inspired fraction of oxygen

UNDER PEER REVIEW